Nuedexta ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03883581 (ClinicalTrials.gov)	July 25, 2019	12/3/2019	Impact of Nuedexta on Bulbar Physiology and Function in ALS	Impact of Nuedexta on Bulbar Physiology and Function in ALS	Amyotrophic Lateral Sclerosis	Drug: dextromethorphan HBr and quinidine sulfate	University of Florida	Holy Cross Hospital, Florida;ALS Association	Completed	18 Years	90 Years	All	28	Phase 1/Phase 2	United States
2	NCT01806857 (ClinicalTrials.gov)	April 2013	5/3/2013	Clinical Trial Nuedexta in Subjects With ALS	The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS)	Drug: Nuedexta;Drug: Matching Placebo	Center for Neurologic Study, La Jolla, California,	ALS Association;State University of New York - Upstate Medical University	Completed	18 Years	N/A	All	90	Phase 2	United States